Navigation Links
PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor Vlla At 2012 ASH Annual Meeting
Date:12/7/2012

Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect PROLOR's business and prospects, including the risks that PROLOR may not succeed in generating any revenues or developing any commercial products, including any long-acting versions of human growth hormone, erythropoietin, interferon beta, GLP-1 and other products; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; that the actual dollar amount of any grants from Israel's Office of the Chief Scientist is uncertain and is subject to policy changes of the Israeli government, and that such grants may be insufficient to assist with product development; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in PROLOR's filings with the Securities and Exchang
'/>"/>
SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. GenWay Biotech Appoints New Vice President of Custom/OEM
2. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
3. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
4. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
5. TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin, to Zhejiang Medicine
6. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
7. Obamacare Ruling, Other Pivotal News Rocks Biotech Sector in June
8. Tougher Times May be Ahead for Biotechs: 1H12 Fundraising Slows
9. Last Chance to Save on Boston-Area Mobile Health, Biotech, and Pharmaceutical Conference Registration
10. Early Birds Save Up to $600 on Asian Biotech and Pharmaceutical Conferences
11. Lifeline Biotechnologies First Warning Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015  Delays in the launch and execution ... the decision-making process, resulting in missed opportunities and ... biopharmaceutical companies to develop a tactical approach to ... and more meaningful insights. According ... three-quarters of benchmarked study participants use review cycle ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... Capacity and Production" report to their offering. ... Survey of Biopharmaceutical Manufacturing Capacity and Production is ... contract manufacturing organizations, current and projected future capacity ...
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Insulin Aspart Market, ... Developed by Novo Nordisk, insulin aspart (under the ... for the treatment of diabetes. Compared with human ... analog, starts working fast and reports higher peak ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2
... 30 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), a leading ... volunteer enrollment in its Phase II clinical trial for ... study,are expected to be available in early 2009., ... 210,adolescents, between the ages of 12 to 17, who ...
... Set for Sept. 29, LA JOLLA, Calif., ... ) today announced that data presented at the ... showed that, in,addition to meeting the primary endpoint ... lead AMPA/kainate-type glutamate receptor antagonist,tezampanel, demonstrated improvement on ...
Cached Medicine Technology:Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine 2Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine 3Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel 2Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel 3
(Date:8/30/2015)... ... August 30, 2015 , ... Certified Nutrition Businessman Reid Eckert ... International and InHealth media is a global sales and communications firm that offers U.S. ... to continue our business relationship with Mr. Reid Eckert, as his interpretation of the ...
(Date:8/30/2015)... ... August 30, 2015 , ... SonaCare Medical, LLC, ... treatment of prostate cancer, has announced the roll-out of its newest technology – ... in Puerto Vallarta, Mexico. , The Sonablate® technology currently in use at the ...
(Date:8/29/2015)... Falls Church, VA (PRWEB) , ... August 30, ... ... Practices, **FDAnews Webinar**, Sept. 15, 2015 — 1:30 p.m. – 3:00 p.m. EDT, ... it's much more than a simple digital handwritten signature. , Clinical ...
(Date:8/29/2015)... ... August 29, 2015 , ... It can be ... against dribbled urine and sweat. "In order to prevent these problems, I conceived ... ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal support for a male’s crotch. It ...
(Date:8/29/2015)... ... ... Brands like Toppik , Eau Thermale Avene and Bliss are now available ... $49.00 was required to qualify for free standard shipping,” said Jennifer Ramirez, the public ... regardless of the item’s selling price.” , With competitive pricing in the e-commerce market ...
Breaking Medicine News(10 mins):Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2
... Corporation,(CRM:TSX-V) announced today that it has opened a Center ... the Company,s second in the,Miami area, one of many ... of the Pembroke Pines Center brings the Company,s total ... Institute of Health, the prevalence rate of,hemorrhoids in the ...
... C-Span did to open,the door on Congressional proceedings ... is doing for medical professionals via its live,coverage ... Today is the innovative source of medical news ... credit to,physicians and other clinicians., From March ...
... The Bill & Melinda Gates Foundation,announced today that ... first,round of Grand Challenges Explorations, a US$100 million ... Proposals will,be accepted online at http://www.gcgh.org/explorations ... to submit a proposal by May 15,2008., ...
... Softgel Supplements Formulated for Easy Swallowing and ... ... Many things in life are,hard to swallow, but your vitamins shouldn,t ... a new,way to fuel the body with a complete product line ...
... to reach out to,wounded soldiers, Retired Army Reserve Lieutenant ... uplifting and rejuvenating weekend,retreats -- offered at no cost ... and relaxation for soldiers hurt in Iraq and Afghanistan., ... Terrorists,these brave men and women are now embarking on ...
... 2008) Real-world use of a novel drug-eluting stent ... clinical outcomes, according to one-year data from a large ... on the sirolimus-eluting Excel stent, are being reported today ... Annual Scientific Sessions in Partnership with ACC i2 Summit ...
Cached Medicine News:Health News:CRH Medical Corporation opens new center in Pembroke Pines Florida 2Health News:MedPage Today(R) Provides First-Time Live Video Coverage of Medical Meeting Press Conferences 2Health News:Gates Foundation Now Accepting Proposals for Grand Challenges Explorations 2Health News:Nature Made(R) Changes the Way America Takes Vitamins 2Health News:Nature Made(R) Changes the Way America Takes Vitamins 3Health News:Healing Wounds and Hearts: Warrior Weekend Helps Soldiers Relax and Recover 2Health News:Registry unveils 'real-world' data on novel excel stent 2
Inquire...
Remote Blower With Bag-In/Bag-Out Option...
Class II Type B1 Biological Safety Cabinet...
Built-in, motor-driven internal calibration mass for convenient Touch-key calibration. Also capable of touch-key calibration with external weights. Built-in RS232 Interface, Shimadzu WindowsDirect ...
Medicine Products: